NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands unless otherwise
indicated)
|
1.
|
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION
|
Bioanalytical Systems, Inc.
and its subsidiaries, including as operating under the trade name “Inotiv” (“We,” “Our,” “Us,”
the “Company,” “BASi” and “Inotiv”) engage in contract laboratory research services and other
services related to pharmaceutical development, chemical and medical device development, biomedical research and government-sponsored
research. The Company also manufactures scientific instruments for life sciences research, which we sell with related software
for use by pharmaceutical companies, universities, government research centers and medical research institutions. Our customers
are located throughout the world.
2.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
|
(a)
|
Principles of Consolidation
|
The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions
have been eliminated.
|
(b)
|
Reclassification of Prior Year Presentation
|
Certain prior year
amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the
reported results of operations.
In accordance with
Accounting Standards Codification (“ASC”) 606, the Company disaggregates its revenue from clients into three revenue
streams, service revenue, product revenue and royalties. At contract inception the Company assesses the services promised in the
contract with the clients to identify performance obligations in the arrangements.
Service revenue
The Company enters
into contracts with clients to provide drug discovery and development services with payments based on mainly fixed-fee arrangements.
The Company also offers archive storage services to our clients.
The Company’s
fixed fee arrangements may involve nonclinical research services (toxicology, pathology, pharmacology), bioanalytical, and pharmaceutical
method development and validation, nonclinical research services and the analysis of bioanalytical and pharmaceutical samples.
For bioanalytical and pharmaceutical method validation services and nonclinical research services, revenue is recognized over time
using the input method based on the ratio of direct costs incurred to total estimated direct costs. For contracts that involve
in-life study conduct, method development or the analysis of bioanalytical and pharmaceutical samples, revenue is recognized over
time when samples are analyzed or when services are performed. The Company generally bills for services on a milestone basis. These
contracts represent a single performance obligation and due to the Company’s right to payment for work performed, revenue
is recognized over time. Research services contract fees received upon acceptance are deferred until earned and classified within
customer advances on the consolidated balance sheets. Unbilled revenues represent revenues earned under contracts in
advance of billings.
Archive services provide
climate controlled archiving for client’s data and samples. The archive revenue is recognized over time, generally when the
service is provided. These arrangements include one performance obligation. Amounts related to future archiving or prepaid archiving
contracts for clients where archiving fees are billed in advance are accounted for as deferred revenue and recognized ratably over
the period the applicable archive service is performed.
Product revenue
The Company’s
products can be sold to multiple clients and have alternative use. Both the transaction sales price and shipping terms are agreed
upon in the client order. For these products, all revenue is recognized at a point in time, generally when title of the product
and control is transferred to the client based upon shipping terms. These arrangements typically include only one performance obligation.
Certain products have maintenance agreements available for clients to purchase. These are typically billed in advance and are accounted
for as deferred revenue, are recognized ratably over the applicable maintenance period and are included in customer advances on
the consolidated balance sheet.
Royalty revenue
The Company has an
agreement with Teva Pharmaceuticals (formerly Biocraft Laboratories, Inc,) which manufactures and markets pharmaceutical products.
The Company receives royalties in accordance with sales of certain pharmaceuticals that Teva manufactures and sells. The royalties
are received on a quarterly basis and the revenue is recognized over the quarter. Royalty revenue is included in service revenue
on the consolidated statement of operations. Total revenue recognized was $641 and $349 in the years ended September 30, 2020 and
2019, respectively.
The following table
presents changes in the Company’s contract liabilities for the year ended September 30, 2020.
|
|
Fiscal year ended
September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Opening balance
|
|
$
|
6,726
|
|
|
$
|
4,925
|
|
Additions
|
|
|
106,956
|
|
|
|
34,650
|
|
Deductions
|
|
|
(102,290
|
)
|
|
|
(32,849
|
)
|
Ending balance
|
|
$
|
11,392
|
|
|
$
|
6,726
|
|
The Company considers
all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Accounts
are insured by the Federal Deposit Insurance Corporation (FDIC) up to certain limits. At times, cash in the bank deposit may exceed
federally insured limits.
The Company performs
periodic credit evaluations of our clients’ financial conditions and generally do not require collateral on trade accounts
receivable. We account for trade receivables based on the amounts billed to clients. Past due receivables are determined based
on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined
by management based on our historical losses, specific client circumstances, and general economic conditions. Periodically, management
reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables
when all attempts to collect have failed. Our allowance for doubtful accounts was $561 and $1,759 at September 30, 2020 and
2019, respectively. A summary of activity in our allowance for doubtful accounts is as follows:
|
|
Fiscal year ended
September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Opening balance
|
|
$
|
1,759
|
|
|
$
|
1,948
|
|
Charged to expense
|
|
|
180
|
|
|
|
-
|
|
Uncollectible invoices written off
|
|
|
(1,378
|
)
|
|
|
(49
|
)
|
Amounts collected
|
|
|
-
|
|
|
|
(140
|
)
|
Ending balance
|
|
$
|
561
|
|
|
$
|
1,759
|
|
Inventories are stated
at the lower of cost or net realizable value using the first-in, first-out (FIFO) cost method of accounting. The Company evaluates
inventory on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market
demand. For inventory deemed to be obsolete, we provide a reserve. Inventory that is in excess of current and projected use is
reduced by an allowance to a level that approximates the estimate of future demand. A summary of activity in our inventory obsolescence
is as follows for the years ended September 30, 2020 and 2019:
|
|
Fiscal year ended
September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Opening balance
|
|
$
|
198
|
|
|
$
|
188
|
|
Provision for slow moving and obsolescence
|
|
|
84
|
|
|
|
97
|
|
Write-off of obsolete and slow moving inventory
|
|
|
(105
|
)
|
|
|
(87
|
)
|
Closing balance
|
|
$
|
177
|
|
|
$
|
198
|
|
|
(g)
|
Property and Equipment
|
The Company records
property and equipment acquired as part of business combinations at fair value while other property and equipment is recorded at
cost, including interest capitalized during the period of construction of major facilities. Depreciation, including amortization
on capital leases, is computed using the straight-line method over the estimated useful lives of the assets, which we estimate
to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10
years. Expenditures for maintenance and repairs are expensed as incurred unless the life of the asset is extended beyond one year,
which would qualify for asset treatment. Depreciation expense was $3,126 in fiscal 2020 and $2,223 in fiscal 2019. Property and
equipment, net, as of September 30, 2020 and 2019 consisted of the following:
|
|
2020
|
|
|
2019
|
|
Land and improvements
|
|
$
|
1,755
|
|
|
$
|
1,048
|
|
Buildings and improvements
|
|
|
29,882
|
|
|
|
22,418
|
|
Machinery and equipment
|
|
|
30,731
|
|
|
|
25,323
|
|
Office furniture and fixtures
|
|
|
950
|
|
|
|
905
|
|
Construction in progress
|
|
|
718
|
|
|
|
6,010
|
|
|
|
|
64,036
|
|
|
|
55,704
|
|
Less: accumulated depreciation
|
|
|
(35,307
|
)
|
|
|
(32,876
|
)
|
Net property and equipment
|
|
$
|
28,729
|
|
|
$
|
22,828
|
|
|
(h)
|
Long-Lived Assets including Goodwill
|
Long-lived assets,
such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge
is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.
The Company carries
goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over
their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable
of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill
is not amortized. At September 30, 2020 and 2019, respectively, the remaining recorded goodwill
was $4,368 and $3,617. The increase of $751 is attributable to the Pre-clinical Research Services, Inc., (PCRS) acquisition
as described in Note 11.
The Company reviews
goodwill for impairment on an annual basis in accordance with ASC 350, Intangibles- Goodwill and Other. In evaluating the
goodwill, we must make assumptions regarding the discounted future cash flows of the reporting unit with goodwill. If the discounted
cash flows are less than the carrying value, we then determine if an impairment loss is recognized by evaluating the fair value
of the goodwill. The Company utilizes fair value techniques accepted by ASC 820, which include the income, market and cost approach. If
the fair value of the goodwill is less than the carrying amount, we recognize an impairment loss. Considerable management judgment
is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used
in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the
best available market information. Changes in these estimates or a continued decline in general economic conditions could change
our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The
assumptions used in our impairment testing could be adversely affected by certain risks.
The Company had one
reporting unit with goodwill at September 30, 2020 which was our Services business, which is included in our Services operating
segment, based on the discrete financial information available which is reviewed by management. An annual goodwill impairment test
was performed for the Services reporting unit at September 30, 2020 and there was no indication of impairment. There have
been no significant events since the timing of our impairment tests that would have triggered additional impairment testing after
fiscal year-end.
At September 30,
2020 the intangible assets subject to amortization totaled $4,261 as compared to $2,883 at September 30, 2019. The increase
in intangible assets relate to the PCRS acquisition described in Note 11. The changes in the balances of the intangible assets
for the years ended September 30, 2020 and 2019 are as follows:
|
|
Trademarks
|
|
|
Client
Relationships
|
|
|
Non-Compete
Agreements
|
|
|
Backlog
|
|
|
Patents
|
|
|
Totals
|
|
Balance as of October 1, 2018
|
|
$
|
1,150
|
|
|
$
|
1,918
|
|
|
$
|
178
|
|
|
$
|
72
|
|
|
$
|
16
|
|
|
$
|
3,334
|
|
Amortization
|
|
|
(78
|
)
|
|
|
(248
|
)
|
|
|
(47
|
)
|
|
|
(72
|
)
|
|
|
(6
|
)
|
|
|
(451
|
)
|
Balance as of September 30, 2019
|
|
$
|
1,072
|
|
|
$
|
1,670
|
|
|
$
|
131
|
|
|
$
|
-
|
|
|
$
|
10
|
|
|
$
|
2,883
|
|
Acquisition of PCRS
|
|
|
460
|
|
|
|
1,280
|
|
|
|
220
|
|
|
|
121
|
|
|
|
-
|
|
|
|
2,081
|
|
Amortization
|
|
|
(103
|
)
|
|
|
(380
|
)
|
|
|
(93
|
)
|
|
|
(121
|
)
|
|
|
(6
|
)
|
|
|
(703
|
)
|
Balance as of September 30, 2020
|
|
$
|
1,429
|
|
|
$
|
2,570
|
|
|
$
|
258
|
|
|
$
|
-
|
|
|
$
|
4
|
|
|
$
|
4,261
|
|
Future amortization
expense for intangible assets at September 30, 2020 for the next five years and a total, thereafter, are as follows:
|
|
2021
|
|
|
2022
|
|
|
2023
|
|
|
2024
|
|
|
2025
|
|
|
Thereafter
|
|
|
Totals
|
|
Trademarks
|
|
|
109
|
|
|
|
109
|
|
|
|
109
|
|
|
|
109
|
|
|
|
109
|
|
|
|
884
|
|
|
|
1,429
|
|
Client Relationships
|
|
|
408
|
|
|
|
408
|
|
|
|
408
|
|
|
|
408
|
|
|
|
408
|
|
|
|
530
|
|
|
|
2,570
|
|
Non-Compete Agreements
|
|
|
102
|
|
|
|
91
|
|
|
|
55
|
|
|
|
10
|
|
|
|
-
|
|
|
|
-
|
|
|
|
258
|
|
Patents
|
|
|
4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4
|
|
|
|
$
|
623
|
|
|
$
|
608
|
|
|
$
|
572
|
|
|
$
|
527
|
|
|
$
|
517
|
|
|
$
|
1,414
|
|
|
$
|
4,261
|
|
|
(i)
|
Stock-Based Compensation
|
The Company has a stock
option plan and an equity incentive plan for officers, outside directors and employees, which are described more fully in Note
9.
The Company recognizes
the cost resulting from all share-based payment transactions in our financial statements using a fair-value based method. Compensation
cost for all share-based awards are measured based on estimated fair values and compensation is recognized over the vesting period
for awards.
The Company uses the
binomial option valuation model to determine the grant date fair value. The determination of fair value is affected by our common
share price as well as assumptions regarding subjective and complex variables such as expected employee exercise behavior and our
expected stock price volatility over the term of the award. Generally, our assumptions are based on historical information and
judgment is required to determine if historical trends may be indicators of future outcomes. We estimated the following key assumptions
for the binomial valuation calculation:
|
·
|
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury yields in
effect at the time of grant for the expected term of the option.
|
|
·
|
Expected volatility. The Company uses our historical share price volatility on our common
shares for our expected volatility assumption.
|
|
·
|
Expected term. The expected term represents the weighted-average period the stock options
are expected to remain outstanding. The expected term is determined based on historical exercise behavior, post-vesting termination
patterns, options outstanding and future expected exercise behavior.
|
|
·
|
Expected dividends. The Company assumes that we will pay no dividends.
|
Employee stock-based compensation
expense recognized in fiscal 2020 and 2019 was calculated based on awards ultimately expected to vest and has been reduced for
estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates
and an adjustment will be recognized at that time.
Income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. We record valuation allowances based on a determination of the expected realization of tax assets.
The Company may recognize
the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the
technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit
determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.
The Company records
interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes
in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized
tax benefits to significantly change in the next twelve months.
|
(k)
|
Fair Value of Financial Instruments
|
The provisions of the
Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and
provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in
measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that
the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the
asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs
that reflect the Company’s judgment about the assumptions market participants would use in pricing the asset or liability
based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs
as follows:
|
·
|
Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
|
|
·
|
Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
|
|
·
|
Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
|
The carrying amounts
for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other
accruals approximate their fair values because of their nature and respective duration. The carrying value of the credit facility
approximates fair value as it was amended during fiscal year 2020 and subsequent to the amendment, there have been no factors that
would indicate a change in the carrying value
As
of September 30, 2020 and 2019, the Company did not have any financial assets or liabilities measured at fair value on a recurring
basis.
The preparation of
the consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates
and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates
as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values,
allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation.
Our actual results could differ from those estimates.
|
(m)
|
Research and Development
|
In fiscal 2020 and
2019, the Company incurred $950 and $627, respectively, on research and development. Separate from our contract research services
business, we maintain applications research and development to enhance our products business. The Company expenses research and
development costs as incurred.
The Company capitalizes
costs associated with the issuance of debt and amortizes them as additional interest expense over the lives of the debt on a straight-line
basis, which approximates the effective interest method. The Company believes the difference between the straight-line basis and
the effective interest method is not material to the consolidated financial statements. Debt issuance costs of $235 and $207, as
of September 30, 2020 and 2019, respectively, were netted with long-term debt less current portion on the consolidated balance
sheets. Upon prepayment of the related debt, the Company accelerates the recognition of an appropriate amount of the costs as refinancing
or extinguishment of debt.
|
(o)
|
New Accounting Pronouncements
|
In February 2016,
the Financial Accounting Standards Board (“FASB”) issued updated guidance on leases which, for operating leases, requires
a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments,
in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the
lease is allocated over the lease term, on a generally straight-line basis. The guidance is effective for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted.
On October 1,
2019, the Company adopted ASC 842 Leases (ASU 2016-02) and all the related amendments to its lease contracts using the modified
retrospective method. The effective date was used as the Company’s date of initial application with no restatement of prior
periods. As such prior periods continue to be reported under the accounting standards in effect for those periods. The Company
recorded upon adoption a financing right-of-use asset and lease liability on the consolidated balance sheet of $4,628 and $4,650,
respectively, and an operating right-of-use asset and lease liability of $4,581 and $4,687, respectively. The lease liability reflects
the present value of the Company’s estimated future minimum lease payments over the term of the lease, which includes options
that are reasonably certain to be exercised, discounted utilizing a collateralized incremental borrowing rate. The impact of the
new lease standard does not affect the Company’s operating cash flows. See Note 6 for additional information.
In June 2016,
the FASB issued ASU 2016-13 “Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instrument”
“CECL”). ASU 2016-13 requires an allowance for expected credit losses on financial assets to be recognized as early
as day one of the instrument. This ASU departs from the incurred loss model which means the probability threshold is removed.
It considers more forward-looking information and requires the entity to estimate its credit losses as far as it can reasonably
estimate. This update became effective for the Company on October 1, 2020. The adoption of this guidance did not have a material
impact on the Company’s consolidated financial statements.
The Lease Agreement
with Cook Biotech, Inc. (“lessee”) for a portion of the Company’s headquarters facility is recorded as an
operating lease with the escalating rents being recognized on a straight-line basis once the lessee took full possession of the
space on May 1, 2015 through the end of the lease on December 31, 2024. The straight-line rents of $53 per month are
recorded as a reduction to general and administrative expenses on the consolidated statements of operations and other accounts
receivable on the consolidated balance sheets. The cash rent received is recorded in lease rent receivable on the consolidated
balance sheets. The variance between the straight-line rents recognized and the actual cash rents received will net to zero by
the end of the agreement on December 31, 2024.
3. SALE OF PREFERRED SHARES AND WARRANTS
(not in thousands)
On May 11, 2011,
the Company completed a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consisted of one 6%
Series A convertible preferred share which is convertible into 500 common shares. The Series A preferred shares were
valued using the common shares available upon conversion of all preferred shares of 2,753,000 and the closing market price of our
stock on May 11, 2011 of $1.86. As of September 30, 2020, 5,481 preferred shares have been converted into 3,144,108 common
shares and 217,366 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred
shares. At September 30, 2020, 25 preferred shares remained outstanding. All dividends have been paid according to the agreement.
4. LOSS PER SHARE
The Company computes
basic income (loss) per share using the weighted average number of common shares outstanding. The Company has two categories of
dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered
direct offering and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method
for preferred stock and the treasury stock method for stock options, respectively. Shares issuable upon exercise of 712 stock options
and 12 common shares issuable upon conversion of preferred shares were not considered in computing diluted income (loss) per share
for the year ended September 30, 2020, because they were anti-dilutive. Shares issuable upon exercise of 776 stock options
and 17 common shares issuable upon conversion of preferred shares were not considered in computing diluted income (loss) per share
for the year ended September 30, 2019, because they were anti-dilutive.
Computation of basic
net loss per share is shown in the following table:
|
|
Years Ended September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Basic net (loss) per share:
|
|
|
|
|
|
|
|
|
Net loss applicable to common shareholders
|
|
$
|
(4,685
|
)
|
|
$
|
(790
|
)
|
Weighted average common shares outstanding
|
|
|
10,851
|
|
|
|
10,383
|
|
Basic net loss per share
|
|
$
|
(0.43
|
)
|
|
$
|
(0.08
|
)
|
For purposes of the diluted net income (loss) per share calculation,
stock options and Series A preferred shares are considered to be common stock equivalents and are only included in the calculation
of diluted net loss per share when their effect is dilutive. These common stock equivalents were excluded from the determination
of diluted net loss per share in fiscal 2020 due to their anti-dilutive effect on earnings.
5. INVENTORIES
Inventories consisted of the following:
|
|
As of September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Raw materials
|
|
$
|
577
|
|
|
$
|
858
|
|
Work in progress
|
|
|
70
|
|
|
|
89
|
|
Finished goods
|
|
|
230
|
|
|
|
346
|
|
|
|
$
|
877
|
|
|
$
|
1,293
|
|
Obsolescence reserve
|
|
|
(177
|
)
|
|
|
(198
|
)
|
|
|
$
|
700
|
|
|
$
|
1,095
|
|
6. LEASES
The Company has various operating and finance
leases for facilities and equipment. Facilities leases provide office, laboratory, warehouse, or land, the Company uses to conduct
its operations. Facilities leases range in duration from two to ten years, with either renewal options for additional terms as
the initial lease term expires, or purchase options. Facilities leases are considered as either operating or financing leases.
Equipment leases provide for office equipment,
laboratory equipment or services the Company uses to conduct its operations. Equipment leases range in duration from 30 to 60 months,
with either subsequent annual renewals, additional terms as the initial lease term expires, or purchase options.
Effective October 1, 2019, the Company
adopted ASC 842, Leases, using a modified retrospective transition approach which applies the standard to leases existing at the
effective date with no restatement of prior periods. The Company’s operating leases have been included in operating lease
right-of-use assets, current portion of operating lease liabilities and long-term portion of operating lease liabilities in the
consolidated balance sheet. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term
and lease liabilities represent its obligation to make lease payments arising from the leases.
The Company elected to apply the following
practical expedients and accounting policy elections permitted by the standard at transition:
|
·
|
The Company has elected that it will not reassess contracts that have expired or existed at the date of adoption for 1) leases
under the new definition of a lease, 2) lease classification, 3) whether previously capitalized initial direct costs would qualify
for capitalization under the standard.
|
|
·
|
The Company elected not to separate lease and non-lease components.
|
|
·
|
The Company elected not to assess whether any land easements are, or contain, leases.
|
|
·
|
The Company elected to record leases with an initial term of 12 months or less directly in the consolidated statement of
operations.
|
Right-of-use lease assets and lease liabilities
that are reported in the Company’s consolidated balance sheets are as follows:
|
|
As of
|
|
|
|
September 30, 2020
|
|
Operating right-of-use assets, net
|
|
$
|
4,001
|
|
|
|
|
|
|
Current portion of operating lease liabilities
|
|
|
866
|
|
Long-term operating lease liabilities
|
|
|
3,344
|
|
Total operating lease liabilities
|
|
$
|
4,210
|
|
|
|
|
|
|
Finance right-of-use assets, net
|
|
$
|
4,778
|
|
|
|
|
|
|
Current portion of finance lease liabilities
|
|
|
4,728
|
|
Long-term finance lease liabilities
|
|
|
44
|
|
Total finance lease liabilities
|
|
$
|
4,772
|
|
During the twelve months
ended September 30, 2020, the Company had operating lease amortizations of $906, and finance lease amortization of $145. Finance
lease interest recorded in the twelve months ended September 30, 2020 was $283.
One of the operating
leases contains a variable lease component based on revenue for one component of the Company. The total variable payments for this lease for fiscal
year 2020 was $126.
Lease expense for lease
payments is recognized on a straight-line basis over the lease term. The components of lease expense related to the Company’s
lease for the twelve months ended September 30, 2020 were:
|
|
Twelve months
ended
|
|
|
|
September 30, 2020
|
|
Operating lease costs:
|
|
|
|
|
Fixed operating lease costs
|
|
$
|
906
|
|
Short-term lease costs
|
|
|
41
|
|
Variable lease costs
|
|
|
1
|
|
Sublease income
|
|
|
(636
|
)
|
Finance lease costs:
|
|
|
|
|
Amortization of right-of-use asset expense
|
|
|
145
|
|
Interest on finance lease liability
|
|
|
283
|
|
Total lease cost
|
|
$
|
740
|
|
The Company serves
as lessor to a lessee in one facility through the end of calendar year 2024. The gross rental income and underlying lease expense
are presented gross in the Company’s consolidated balance sheet. The Company received rental income of $636 for twelve months
ended September 30, 2020.
Supplemental cash flow information related
to leases was as follows:
|
|
Twelve months
Ended
|
|
|
|
September 30, 2020
|
|
Cash flows included in the measurement of lease liabilities:
|
|
|
|
|
Operating cash flows from operating leases
|
|
$
|
948
|
|
Operating cash flows from finance leases
|
|
|
283
|
|
Finance cash flows from finance leases
|
|
|
145
|
|
Non-cash lease activity:
|
|
|
|
|
Right-of-use assets obtained in exchange for new operating lease liabilities
|
|
$
|
448
|
|
The weighted average remaining lease term
and discount rate for the Company’s operating and finance leases as of September 30, 2020 were:
|
|
As of
|
|
|
|
September 30, 2020
|
|
Weighted-average remaining lease term (in years)
|
|
|
|
|
Operating lease
|
|
|
4.81
|
|
Finance lease
|
|
|
0.88
|
|
Weighted-average discount rate (in percentages)
|
|
|
|
|
Operating lease
|
|
|
5.23
|
%
|
Finance lease
|
|
|
5.87
|
%
|
Lease duration was determined utilizing
renewal options that the Company is reasonably certain to execute.
As of September 30,
2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as
follows:
|
|
Operating Leases
|
|
|
Finance Leases
|
|
2021
|
|
$
|
896
|
|
|
$
|
4,929
|
|
2022
|
|
|
938
|
|
|
|
19
|
|
2023
|
|
|
979
|
|
|
|
13
|
|
2024
|
|
|
1,349
|
|
|
|
13
|
|
2025
|
|
|
452
|
|
|
|
5
|
|
Thereafter
|
|
|
194
|
|
|
|
—
|
|
Total minimum future lease payments
|
|
|
4,808
|
|
|
|
4,979
|
|
Less interest
|
|
|
(598
|
)
|
|
|
(207
|
)
|
Total lease liability
|
|
|
4,210
|
|
|
|
4,772
|
|
7. DEBT
Credit Facility
On December 1, 2019,
in connection with the PCRS Acquisition, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”)
with First Internet Bank of Indiana (“FIB”). The Credit Agreement was amended on March 27, 2020 to modify the
definition of Adjusted EBITDA for purposes of covenant calculations and to modify the terms of the Initial Capex Line. The Credit
Agreement includes five term loans (the “Initial Term Loan,” “Second Term Loan,” “Third Term Loan,”
“Fourth Term Loan,” and “Fifth Term Loan,” respectively), a revolving line of credit (the “Revolving
Facility”), a construction draw loan (the “Construction Draw Loan”), an equipment draw loan (the “Equipment
Draw Loan”), and two capital expenditure instruments (the “Initial Capex Line” and the “Second Capex Line,”
respectively).
The Initial Term Loan
for $4,500 bears interest at a fixed rate of 3.99%, with monthly principal and interest payments of approximately $33. The Initial
Term Loan matures June 23, 2022. The balance on the Initial Term Loan at September 30, 2020 was $3,748. We used the proceeds
from the Initial Term Loan to satisfy our indebtedness with Huntington Bank and terminated the related interest rate swap.
The Second Term Loan
for $5,500 was used to fund a portion of the cash consideration for the Seventh Wave acquisition. Amounts outstanding under the
Second Term Loan bear interest at a fixed per annum rate of 5.06%, with monthly principal and interest payments equal to $78. The
Second Term Loan matures July 2, 2023 and the balance on the Second Term Loan at September 30, 2020 was $4,004.
The Third Term Loan
for $1,271 was used to fund the cash consideration for the Smithers Avanza acquisition. Amounts outstanding under the Third Term
Loan bear interest at a fixed per annum rate of 4.63%. The Third Term Loan required monthly interest only payments until December 1,
2019, from which time payments of principal and interest in monthly installments of $20 are required, with all accrued but unpaid
interest, cost and expenses due and payable at the maturity date. The Third Term Loan matures November 1, 2025 and the balance
on the Third Term Loan at September 30, 2020 was $1,115.
The Fourth Term Loan
in the principal amount of $1,500 has a maturity of June 1, 2025. Interest accrues on the Fourth Term Loan at a fixed per
annum rate equal to 4%, with interest payments only commencing January 1, 2020 through June 1, 2020, with monthly payments
of principal and interest thereafter through maturity. The balance on the Fourth Term Loan at September 30, 2020 was $1,425.
The Fifth Term loan
in the principal amount of $1,939 has a maturity of December 1, 2024. Interest accrues on the Fifth Term Loan at a fixed per
annum rate equal to 4%, with payments of principal and interest due monthly through maturity. The balance on the Fifth Term Loan
at September 30, 2020 was $1,891. We entered into the Fourth Term Loan and the Fifth Term Loan in connection with the PCRS
Acquisition.
The Revolving Facility
provides a line of credit for up to $5,000, which the Company may borrow from time to time, subject to the terms of the Credit
Agreement, including as may be limited by the amount of the Company’s outstanding eligible receivables. As of September 30,
2020, the Revolving Facility had a maturity of January 31, 2021. The Revolving Facility requires monthly accrued and unpaid
interest payments only until maturity at a floating per annum rate equal to the greater of (a) 4%, or (b) the sum of
the Prime Rate plus Zero Basis Points (0.0%), which rate shall change concurrently with the Prime Rate. The Company did not have
an outstanding balance on the Revolving Facility as of September 30, 2020. On December 18, 2020, the parties amended the Revolving
Note to extend its maturity through May 31, 2021. Refer to Item 9B.
The Construction Draw
Loan provides for borrowings up to a principal amount not to exceed $4,445 and the Equipment Draw Loan provides for borrowings
up to a principal amount not to exceed $1,429. The Construction Draw Loan and Equipment Draw Loan each mature on March 28,
2025. As of September 30, 2020, there was a $4,230 balance on the Construction Draw Loan and a $1,266 balance on the Equipment
Draw Loan.
Subject to certain
conditions precedent, the Construction Draw Loan and an Equipment Draw Loan each permitted the Company to obtain advances aggregating
up to the maximum principal amount available for such loan through March 28, 2020. Amounts outstanding under these loans bear
interest at a fixed per annum rate of 5.20%. The Construction Draw Loan and the Equipment Draw Loan each require monthly payments
of accrued interest on amounts outstanding through March 28, 2020, and thereafter monthly payments of principal and interest
on amounts then outstanding through maturity. We have utilized funds from the Construction Draw Loan and the Equipment Draw Loan
in connection with the Evansville facility expansion.
The Initial Capex Line
previously provided for borrowings up to the principal amount of $1,100, which the Company could borrow from time to time, subject
to the terms of the Credit Agreement. On March 27, 2020, the parties amended the Initial Capex Line to eliminate the revolving
nature of the line in favor of a term loan in the principal amount of $948, equivalent to the amount of borrowings then outstanding
on the Initial Capex Line. As amended, the Initial Capex Line matures on June 30, 2025, and as of September 30, 2020,
had a balance of $920. Interest accrues on the principal balance of the Initial Capex Line at a fixed per annum rate equal to 4%.
The Company is required to pay accrued but unpaid interest on the Initial Capex Line on a monthly basis until June 30, 2020.
Commencing August 1, 2020, and on the first day of each monthly period thereafter until and including on the maturity date,
the Initial Capex Line requires payments of principal and interest in monthly installments equal to $17.
As of September 30,
2020, the Second Capex Line provided for borrowings up to the principal amount of $3,000, subject to the terms of the Credit Agreement,
with a maturity of December 31, 2020 and interest payments only until maturity at a floating per annum rate equal to the greater
of (a) 4%, or (b) the sum of the Prime Rate plus Fifty Basis Points (0.5%), which rate shall change concurrently with
the Prime Rate. At September 30, 2020, the balance on the Second Capex Line was $2,613. On December 18, 2020, the parties
amended the Second Capex Line to eliminate the revolving nature of the line in favor of a term loan in the principal amount of
$3,000, equivalent to the amount of borrowings then outstanding on the Second Capex Line. Refer to Item 9B.
The Company’s
obligations under the Credit Agreement are guaranteed by BAS Evansville, Inc. (“BASEV”), Seventh Wave Laboratories,
LLC, BASi Gaithersburg LLC, as well as Bronco Research Services LLC (“Bronco”), each a wholly owned subsidiary of the
Company (collectively, the "Guarantors"). The Company’s obligations under the Credit Agreement and the Guarantor's
obligations under their respective guaranties are secured by first priority security interests in substantially all of the assets
of the Company and the Guarantors, respectively, mortgages on the Company’s BASEV’s and Bronco’s facilities in
West Lafayette, Indiana, Evansville, Indiana, and Fort Collins, Colorado, respectively, and pledges of the Company’s
ownership interests in its subsidiaries.
As of September 30,
2020, the Credit Agreement included financial covenants consisting of (i) a Fixed Charge Coverage Ratio (as defined in the
Credit Agreement) of not less than 1.25 to 1.0, tested quarterly and measured on a trailing twelve (12) month basis and (ii) beginning
March 31, 2020 a Cash Flow Leverage Ratio (as defined in the Credit Agreement), tested quarterly, as follows: not to exceed
(a) as of March 31, 2020, 5.00 to 1.00, (b) as of June 30, 2020, 4.50 to 1.00, (c) as of September 30,
2020, 4.25 to 1.00 and (d) as of December 31, 2020 and each quarter thereafter, 4.00 to 1.00. An amendment to the Credit
Agreement on March 27, 2020 modified the definition of Adjusted EBITDA, including for purposes of covenant calculations.
As amended, the calculation of Adjusted EBITDA includes (i) the addition of a decreasing amount of proforma EBITDA from Pre-Clinical
Research Services, Inc. (which the Company acquired in the first quarter of fiscal 2020) for each quarter of fiscal 2020
and (ii) the addition or subtraction of certain non-cash expenses or income recognized. Upon an event of default, which includes
certain customary events such as, among other things, a failure to make required payments when due, a failure to comply with covenants,
certain bankruptcy and insolvency events, and defaults under other material indebtedness, FIB may cease advancing funds, increase
the interest rate on outstanding balances, accelerate amounts outstanding, terminate the agreement and foreclose on all collateral.
The Company has also agreed to obtain a life insurance policy in an amount not less than $5,000 for its President and Chief Executive
Officer and to provide FIB an assignment of such life insurance policy as collateral.
The Company entered
into Credit Agreement modifications on August 13, 2020 and December 18, 2020 with FIB. Based in part on the impact of COVID-19
on the Company’s operations and financial performance, FIB suspended testing of the Fixed Charge Coverage Ratio and the Cash
Flow Leverage Ratio for the June 30, 2020 and September 30, 2020 compliance periods, respectively, and suspended testing
of the Fixed Charge Coverage Ratio for the December 31, 2020 compliance period. The December 18, 2020 modification, also revised
the Company’s covenant calculations on a go-forward basis, as described in Item 9B. Absent these suspensions and modifications,
the Company would not have been in compliance with the covenants for the June 30, 2020 and September 30, 2020 measurement periods
and expects that it would not have been in compliance with the covenants for the December 31, 2020 measurement period. Refer to
Item 9B for additional details. The modification on August 13, 2020 updated the definition of Total Funded Debt under the
Credit Agreement to exclude the funding of the Company’s $5,051 loan pursuant to the Paycheck Protection Program (PPP) under
Division A, Title 1 of the CARES Act until the SBA has made a determination regarding forgiveness of the loan. Any PPP loan balance
not forgiven will thereafter immediately be deemed funded debt for purposes of the Total Funded Debt definition.
In addition to the
indebtedness under our Credit Agreement, as part of the Smithers Avanza acquisition, we have an unsecured promissory note payable
to the Smithers Avanza seller in the initial principal amount of $810 made by BASi Gaithersburg and guaranteed by the Company.
The promissory note bears interest at 6.5% with monthly payments and maturity date of May 1, 2022. At September 30, 2020,
the balance on the note payable to the Smithers Avanza seller was $650. As part of the PCRS acquisition, we also have an unsecured
promissory note payable to the PCRS seller in the initial principal amount of $800. The promissory note bears interest at 4.5%
with monthly payments and a maturity date of December 1, 2024. At September 30, 2020, the balance on the note payable
to the PCRS seller was $752.
On April 23, 2020,
the Company was granted a loan (the “Loan”) from Huntington National Bank in the aggregate amount of $5,051, pursuant
to the Paycheck Protection Program (PPP) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The
principal and accrued interest under the Loan is to be repaid in eighteen installments of $283 beginning on November 16, 2020
and continuing monthly until the final payment is due on April 16, 2022. The Company has applied for the forgiveness of the
loan in the amount of $4,851.
Long-term debt is detailed
in the table below.
|
|
As of:
|
|
|
|
September 30,
2020
|
|
|
September 30,
2019
|
|
Initial term loan
|
|
$
|
3,748
|
|
|
$
|
3,990
|
|
Second term loan
|
|
|
4,004
|
|
|
|
4,715
|
|
Third term loan
|
|
|
1,115
|
|
|
|
1,271
|
|
Fourth term loan
|
|
|
1,425
|
|
|
|
-
|
|
Fifth term loan
|
|
|
1,891
|
|
|
|
-
|
|
Initial Capex line
|
|
|
920
|
|
|
|
-
|
|
Subtotal term loans
|
|
|
13,103
|
|
|
|
9,976
|
|
Construction and equipment loans
|
|
|
5,496
|
|
|
|
4,301
|
|
Seller note – Smithers Avanza
|
|
|
650
|
|
|
|
810
|
|
Seller note – Pre-Clinical Research Services
|
|
|
752
|
|
|
|
-
|
|
Paycheck protection program loan
|
|
|
5,051
|
|
|
|
-
|
|
|
|
|
25,052
|
|
|
|
15,087
|
|
Less: Current portion
|
|
|
(5,991
|
)
|
|
|
(1,109
|
)
|
Less: Debt issue costs not amortized
|
|
|
(235
|
)
|
|
|
(207
|
)
|
Total Long-term debt
|
|
$
|
18,826
|
|
|
$
|
13,771
|
|
Cash interest payments
of $1,039 and $566 were made in 2020 and 2019, respectively. The following table summarizes the combined aggregate amount of maturities
over the next five fiscal years:
|
|
2021
|
|
|
2022
|
|
|
2023
|
|
|
2024
|
|
|
2025
|
|
|
Thereafter
|
|
|
Total
|
|
Long-term debt
|
|
$
|
5,991
|
|
|
$
|
8,110
|
|
|
$
|
4,075
|
|
|
$
|
1,608
|
|
|
$
|
5,227
|
|
|
$
|
41
|
|
|
$
|
25,052
|
|
8. INCOME TAXES
Significant components of our deferred tax
assets and liabilities are as follows:
|
|
As of September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Inventory
|
|
$
|
85
|
|
|
$
|
102
|
|
Accrued compensation and vacation
|
|
|
137
|
|
|
|
162
|
|
Accrued expenses and other
|
|
|
172
|
|
|
|
379
|
|
Domestic net operating loss carryforwards
|
|
|
3,580
|
|
|
|
3,282
|
|
Basis difference for intangible assets
|
|
|
457
|
|
|
|
254
|
|
Stock compensation expense
|
|
|
96
|
|
|
|
2
|
|
AMT credit carryover
|
|
|
-
|
|
|
|
31
|
|
Leases
|
|
|
108
|
|
|
|
-
|
|
PPP loan expenses
|
|
|
1,276
|
|
|
|
-
|
|
Total deferred tax assets
|
|
|
5,911
|
|
|
|
4,212
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
|
(143
|
)
|
|
|
(121
|
)
|
Basis difference for fixed assets
|
|
|
(211
|
)
|
|
|
(219
|
)
|
Goodwill
|
|
|
(141
|
)
|
|
|
-
|
|
Total deferred tax liabilities
|
|
|
(495
|
)
|
|
|
(340
|
)
|
|
|
|
|
|
|
|
|
|
Total net deferred tax assets
|
|
|
5,416
|
|
|
|
3,872
|
|
|
|
|
|
|
|
|
|
|
Valuation allowance for net deferred tax assets
|
|
|
(5,557
|
)
|
|
|
(3,841
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax asset (liability)
|
|
$
|
(141
|
)
|
|
$
|
31
|
|
Significant components
of the provision (benefit) for income taxes are as follows as of the year ended September 30:
|
|
2020
|
|
|
2019
|
|
Current:
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
(31
|
)
|
|
$
|
(31
|
)
|
State and local
|
|
|
6
|
|
|
|
4
|
|
Deferred:
|
|
|
|
|
|
|
|
|
Federal
|
|
|
143
|
|
|
|
31
|
|
State and local
|
|
|
29
|
|
|
|
—
|
|
Income tax expense
|
|
$
|
147
|
|
|
$
|
4
|
|
The effective income tax rate on continuing
operations varied from the statutory federal income tax rate as follows:
|
|
2020
|
|
|
2019
|
|
Federal statutory income tax rate
|
|
|
21.0
|
%
|
|
|
21.0
|
%
|
Increases (decreases):
|
|
|
|
|
|
|
|
|
State and local income taxes, net of Federal tax benefit, if applicable
|
|
|
(0.1
|
)%
|
|
|
(0.4
|
)%
|
Other nondeductible expenses
|
|
|
1.3
|
%
|
|
|
(11.5
|
)%
|
Goodwill
|
|
|
(3.1
|
)%
|
|
|
—
|
|
Valuation allowance changes
|
|
|
(22.3
|
)%
|
|
|
(9.6
|
)%
|
Effective income tax rate
|
|
|
(3.2
|
)%
|
|
|
(0.5
|
)%
|
The Company has indefinite-lived
intangible assets related to goodwill. These intangible assets are not amortized for financial reporting purposes; however, they
are tax deductible and therefore amortized over 15 years for tax purposes. As such, deferred income tax expense and a deferred
tax liability arise as a result of the tax deductibility of the assets. The resulting deferred tax liability, which will continue
to increase over time, will have an indefinite life and could remain on the Company’s balance sheet permanently unless there
is impairment of the related assets (for financial reporting purposes), or the business to which those assets relate are disposed
of. The reversal of the deferred tax liability related to the indefinite-lived goodwill cannot be determined or considered a source
of income for valuation allowance purposes. Therefore, the result is a valuation allowance in excess of net deferred tax assets
and a net credit balance (“naked credit” deferred tax liability).
Realization of deferred
tax assets associated with the net operating loss carryforward and credit carryforward is dependent upon generating sufficient
taxable income prior to their expiration. The valuation allowance in fiscal 2020 and 2019 was $5,557 and $3,841, respectively for
our domestic operations. Payments made in fiscal 2020 and 2019 for income taxes amounted to $7 and $7, respectively.
At September 30,
2020, the Company had domestic net operating loss carryforwards for federal tax purposes of $11,859, which expire from September 30,
2032 through 2036. State and local loss carryforwards total approximately $22,506. The majority expire from September 30, 2028
through 2038; however, approximately $465 may be carried forward indefinitely, as they relate to states conforming to the provisions
of the Tax Cuts and Jobs Act which allowed for an indefinite carryforward period of losses generated after December 31, 2017.
The Company may recognize
the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon regulatory examination based
on the technical merits of the position. The amount of the benefit for which an exposure exists is measured as the largest amount
of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement
of the position. There have been no additional gross uncertain tax positions during fiscal 2020 based on any federal or state tax
position.
The Company is no longer
subject to U.S. Federal tax examinations for years before 2016 or state and local for years before 2015, with limited exceptions.
For federal purposes, the tax attributes carried forward could be adjusted through the examination process and are subject to examination
3 years from the date of utilization.
The Company has assessed
the application of Internal Revenue Code Section 382 regarding certain limitations on the future usage of net operating losses.
No limitation applies as of September 30, 2020 and we will continue to monitor activities in the future.
On March 27, 2020,
President Trump signed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, due to the coronavirus pandemic. Among other
things, the legislation provides tax relief for businesses. The Company is still assessing the tax benefit, if any, that it could
receive under this legislation. The Company received a PPP loan of $5,051 and applied for forgiveness of $4,851. Based on satisfaction
of requirements under the CARES Act for forgiveness, the Company has recorded a deferred tax asset for nondeductible expense relating
to the PPP funds of $1,276.
9. STOCK-BASED COMPENSATION
Summary of Equity Plans and Activity
In March 2008,
the Company’s shareholders approved the 2008 Stock Option Plan (the “Plan”) to replace the 1997 Outside Director
Stock Option Plan and the 1997 Employee Stock Option Plan. The purpose of the Plan was to promote our long-term interests by providing
a means of attracting and retaining officers, directors and key employees. The Compensation Committee administered the Plan and
approved the particular officers, directors or employees eligible for grants. Under the Plan, employees were granted the option
to purchase our common shares at fair market value on the day prior to the date of the grant. Generally, options granted vest and
become exercisable in three equal installments commencing one year from date of grant and expire upon the earlier of the employee’s
termination of employment with us, or ten years from the date of grant.
In March 2018,
the Company’s shareholders approved the amendment and restatement of the Plan in the form of the Amended and Restated 2018
Equity Incentive Plan and in March 2020 the shareholders approved a further amendment to increase the number of shares issuable
under the amended and restated plan by 700 and to make corresponding changes to the number of shares issuable as incentive options
and as restricted stock or pursuant to restricted stock units (as amended, the “Equity Plan”). The Company currently
grants equity awards from the Equity Plan. The purpose of the Equity Plan is to promote our long-term interests by providing a
means of attracting and retaining officers, directors and key employees. The maximum number of new common shares that may be granted
under the Equity Plan is 700 shares plus the remaining shares from the 2008 Stock Option Plan. At September 30, 2020, 814
shares remained available for grants under the Plan.
In fiscal 2020, 152
options were granted to employees and independent directors. In fiscal 2019, 503 options were granted to employees and independent
directors. The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30,
2020 and 2019 were as follows:
|
|
2020
|
|
|
2019
|
|
Risk-free interest rate
|
|
|
1.36
|
%
|
|
|
2.47
|
%
|
Dividend yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Volatility of the expected market price of the Company's common shares
|
|
|
76.56
|
%
|
|
|
72.14
|
%
|
Expected life of the options (years)
|
|
|
5.95
|
|
|
|
5.95
|
|
A summary of our stock
option activity for all options and related information for the year ended September 30, 2020, is as follows (in thousands
except for share prices):
|
|
Options
(shares)
|
|
|
Weighted-
Average
Exercise
Price
|
|
|
Weighted-
Average
Remaining
Contractual
Life
|
|
|
Aggregate
Intrinsic
Value
|
|
Outstanding - October 1, 2019
|
|
|
776
|
|
|
$
|
1.61
|
|
|
|
7.98
|
|
|
$
|
1,536
|
|
Exercised
|
|
|
(154
|
)
|
|
$
|
1.56
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
152
|
|
|
$
|
4.56
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(62
|
)
|
|
$
|
2.05
|
|
|
|
|
|
|
|
|
|
Outstanding - September 30, 2020
|
|
|
712
|
|
|
$
|
2.21
|
|
|
|
7.59
|
|
|
$
|
1,939
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2020
|
|
|
281
|
|
|
$
|
1.64
|
|
|
|
6.38
|
|
|
$
|
922
|
|
The aggregate intrinsic
value is the product of the total options outstanding and the net positive difference of our common share price on September 30,
2020 and the options’ exercise price. The total intrinsic value of stock options exercised for fiscal years ended September 30,
2020 and 2019 were $562 and $19, respectively. The weighted average estimated fair value of stock options granted for the fiscal
years ended September 30, 2020 and 2019 were $3.11 and $1.09 per stock option, respectively. As of September 30, 2020,
our total unrecognized compensation cost related to non-vested stock options was $545 and is expected to be recognized over a weighted-average
service period of 2.0 years.
During the year ended
September 30, 2020, the Company granted a total of 126 shares to officers, outside directors and employees. A summary of our
restricted share activity for the year ended September 30, 2020 is as follows:
|
|
Restricted
Shares
|
|
|
Weighted-
Average Grant
Date Fair Value
|
|
Outstanding – September 30, 2019
|
|
|
20
|
|
|
$
|
2.0
|
|
Granted
|
|
|
126
|
|
|
$
|
4.2
|
|
Unvested shares forfeited
|
|
|
(18
|
)
|
|
$
|
4.0
|
|
Outstanding - September 30, 2020
|
|
|
128
|
|
|
$
|
3.9
|
|
As of September 30,
2020, our total unrecognized compensation cost related to unvested restricted stock was $326 and is expected to be recognized over
a weighted-average service period of 1.4 years. The total fair value of the restricted shares granted during the year ended
September 30, 2020 was $528.
Stock-based compensation
expense for employee stock options and restricted stock for the years ended September 30, 2020 and 2019 was $540 and $278,
respectively.
10. RETIREMENT PLAN
The Company has a 401(k) Retirement
Plan (the “Plan”) covering all employees with at least 90 days of service. Under the terms of the Plan, the Company
matches 50% of the first 6% of the employee contribution. The Plan also includes provisions for various contributions which may
be instituted at the discretion of the Board of Directors. The contribution made by the participant may not exceed the annual limits
set by the IRS. Contribution expense was $538 and $374 in fiscal 2020 and 2019, respectively. The contribution expense increased
primarily due to growth in overall headcount through organic growth and the PCRS acquisition in December 2019 as well as changing
the company match from one year of service eligibility to 90 days eligibility.
11. BUSINESS COMBINATIONS
The Company accounts
for acquisitions in accordance with guidance found in ASC 805, Business Combinations. The guidance requires consideration given,
including contingent consideration, assets acquired, and liabilities assumed to be valued at their fair market values at the acquisition
date. The guidance further provides that: (1) in-process research and development will be recorded at fair value as an indefinite-lived
intangible asset; (2) acquisition costs will generally be expensed as incurred, (3) restructuring costs associated with
a business combination will generally be expensed subsequent to the acquisition date; and (4) changes in deferred tax asset
valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense. ASC 805
requires that any excess of purchase price over fair value of assets acquired, including identifiable intangibles and liabilities
assumed, be recognized as goodwill.
Smithers Avanza Toxicology Services LLC acquisition
Overview
On May 1,
2019, the Company, through its wholly-owned subsidiary BASi Gaithersburg LLC (f/k/a Oriole Toxicology Services LLC) (the
“ Smithers Avanza Purchaser”), acquired (the “Smithers Avanza Acquisition”) from Smithers Avanza
Toxicology Services LLC (the “Smithers Avanza Seller”), a consulting-based contract research laboratory located
in Gaithersburg, Maryland, substantially all of the assets used by the Smithers Avanza Seller in connection with the
performance of in-vivo mammalian toxicology CRO services for pharmaceuticals (small molecules and biologics), vaccines, agro
and industrial chemicals, under the terms and conditions of an Asset Purchase Agreement, dated May 1, 2019, among the
Smithers Avanza Purchaser, the Company, the Smithers Avanza Seller and the member of the Smithers Avanza Seller (the
“Smithers Avanza Purchase Agreement”). The total consideration for the Smithers Avanza Acquisition was $2,595,
which consisted of $1,271 in cash, subject to certain adjustments and an indemnity escrow of $125, 200 of the Company’s
common shares valued at $394 using the closing price of the Company’s common shares on April 30, 2019 and an
unsecured promissory note in the initial principal amount of $810 made by the Smithers Avanza Purchaser and guaranteed by the
Company. The promissory note bears interest at 6.5%. The Company funded the cash portion of the purchase price for the
Smithers Avanza Acquisition with cash on hand and the net proceeds from the refinancing of its credit arrangements with
FIB.
The Smithers Avanza
Purchase Agreement contains customary representations, warranties, covenants (including non-competition requirements applicable
to the selling parties for a 5-year period) and indemnification provisions. As contemplated by the Smithers Avanza Purchase Agreement,
on May 1, 2019 the Smithers Avanza Purchaser assumed amended lease arrangements for certain premises in Gaithersburg, Maryland
(the “Lease Arrangements”). Under the Lease Arrangements, the Smithers Avanza Purchaser agreed to lease the premises
for a term of 5 years and 8 months, with two 5-year extensions at the Smithers Avanza Purchaser’s option. Annual minimum
rental payments under the initial term of the Lease Arrangements range from $400 to $600, provided that the Lease Arrangements
provide the Smithers Avanza Purchaser with the option to purchase the premises. The Lease Arrangements include customary rights
upon a default by landlord or tenant.
Accounting for the Transaction
Results are included
in the Company’s results from the acquisition date of May 1, 2019.
The Company’s
allocation of the $2,595 purchase price to Smithers Avanza’s tangible and identifiable intangible assets acquired and liabilities
assumed, based on their estimated fair values as of May 1, 2019, is included in the table below. Goodwill, which is derived
from the enhanced scientific expertise, expanded client base and our ability to provide broader service solutions through a comprehensive
portfolio, is recorded based on the amount by which the purchase price exceeds the fair value of the net assets acquired and is
deductible for tax purposes. The purchase price allocation as of September 30, 2020 was as follows:
|
|
Allocation as
of
September 30,
2020
|
|
Assets acquired and liabilities assumed:
|
|
|
|
|
Receivables
|
|
$
|
1,128
|
|
Property and equipment
|
|
|
1,564
|
|
Prepaid expenses
|
|
|
147
|
|
Goodwill
|
|
|
545
|
|
Accrued expenses
|
|
|
(219
|
)
|
Customer advances
|
|
|
(570
|
)
|
|
|
$
|
2,595
|
|
The allocation of the
purchase price is based on valuations performed to determine the fair value of such assets and liabilities as of the acquisition
date. Goodwill from this transaction is allocated to the Company’s Services segment. Smithers Avanza recorded revenues of
$10,748 and net loss of $596 for the twelve-month period ending September 30, 2020.
PCRS acquisition
Overview
On November 8,
2019, the Company and Bronco Research Services LLC, a wholly owned subsidiary of the Company (the “PCRS Purchaser”),
entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Pre-Clinical Research Services, Inc.,
a Colorado corporation (the “PCRS Seller”), and its shareholder. Pursuant to the Purchase Agreement, on December 1,
2019, the Company indirectly acquired (the “PCRS Acquisition”) substantially all of the assets of PCRS Seller used
or useful by PCRS Seller in connection with PCRS Seller's provision of GLP and non-GLP preclinical testing for the pharmaceutical
and medical device industries. The total consideration for the PCRS Acquisition was $5,857, which consisted of $1,500 in cash,
subject to certain adjustments, 240 of the Company’s common shares valued at $1,133 using the closing price of the Company’s
common shares on November 29, 2019 and an unsecured promissory note in the initial principal amount of $800 made by PCRS Purchaser.
The promissory note bears interest at 4.5%. The Company also purchased certain real property located in Fort Collins, Colorado,
comprising the main facility for the PCRS Seller’s business and additional property located next to the facility available
for future expansion, for $2,500. The Company funded the cash portion of the purchase price for the PCRS Acquisition with cash
on hand and the net proceeds from the refinancing of its credit arrangements with FIB, as described in Note 7. As contemplated
by the Purchase Agreement, the Company also entered into a lease arrangement for an ancillary property used by PCRS Seller’s
business, located in Livermore, Colorado.
Accounting for the Transaction
Results are included
in the Company’s results from the acquisition date of December 1, 2019.
The Company’s
allocation of the $5,857 purchase price to PCRS’s tangible and identifiable intangible assets acquired and liabilities assumed,
based on their estimated fair values as of December 1, 2019, is included in the table below. Goodwill, which is derived from
the enhanced scientific expertise, expanded client base and our ability to provide broader service solutions through a comprehensive
portfolio, is recorded based on the amount by which the purchase price exceeds the fair value of the net assets acquired and is
deductible for tax purposes. The purchase price allocation as of September 30, 2020 was as follows:
|
|
Allocation as of
September 30,
2020
|
|
Assets acquired and liabilities assumed:
|
|
|
|
|
Receivable
|
|
$
|
578
|
|
Property and equipment
|
|
|
2,836
|
|
Unbilled receivables
|
|
|
162
|
|
Prepaid expenses
|
|
|
27
|
|
Intangible assets
|
|
|
2,081
|
|
Goodwill
|
|
|
751
|
|
Accounts payable
|
|
|
(109
|
)
|
Accrued expenses
|
|
|
(118
|
)
|
Customer advances
|
|
|
(351
|
)
|
|
|
$
|
5,857
|
|
The allocation of the
purchase price is based on valuations performed to determine the fair value of such assets and liabilities as of the acquisition
date. Goodwill from this transaction is allocated to the Company’s Services segment. The Company incurred transaction costs
of $248 for the twelve months ended September 30, 2020 related to the PCRS Acquisition. These costs were expensed as
incurred and were primarily recorded as selling, general, and administrative expenses on the Company’s consolidated statements
of operations. PCRS recorded revenues of $4,780 and net income of $176 for the twelve-month period ending September 30,
2020.
Pro Forma Results
The Company’s
unaudited pro forma results of operations for the twelve months ended September 30, 2020 assuming the Smithers Avanza Acquisition
and the PCRS Acquisition had occurred as of October 1, 2019 are presented for comparative purposes below. These amounts are
based on available information of the results of operations of the Smithers Avanza Seller’s operations and the PCRS Seller’s
operations prior to the acquisition date and are not necessarily indicative of what the results of operations would have been had
the Smithers Avanza Acquisition and PCRS Acquisition been completed on October 1, 2019.
The unaudited pro forma
information is as follows:
|
|
Twelve Months
Ended
|
|
|
|
September 30,
2019
|
|
Total revenues
|
|
$
|
51,661
|
|
Net loss
|
|
|
(2,808
|
)
|
|
|
|
|
|
Pro forma basic net loss per share
|
|
$
|
(0.26
|
)
|
Pro forma diluted net loss per share
|
|
$
|
(0.26
|
)
|
12. SEGMENT INFORMATION
The Company operates
in two principal segments - research services and research products. Our Services segment provides research and development support
on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical
and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research
institutions. The accounting policies of these segments are the same as those described in the summary of significant accounting
policies.
|
|
Years Ended September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Revenue:
|
|
|
|
|
|
|
Services
|
|
$
|
57,177
|
|
|
$
|
39,048
|
|
Products
|
|
|
3,292
|
|
|
|
4,568
|
|
|
|
$
|
60,469
|
|
|
$
|
43,616
|
|
Operating income (loss):
|
|
|
|
|
|
|
|
|
Services
|
|
$
|
8,210
|
|
|
$
|
5,579
|
|
Products
|
|
|
(437
|
)
|
|
|
(95
|
)
|
Unallocated corporate
|
|
|
(10,836
|
)
|
|
|
(5,636
|
)
|
|
|
$
|
(3,063
|
)
|
|
$
|
(153
|
)
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(1,490
|
)
|
|
|
(642
|
)
|
Other income
|
|
|
15
|
|
|
|
9
|
|
Income (loss) before income taxes
|
|
$
|
(4,538
|
)
|
|
$
|
(786
|
)
|
|
|
Years Ended September 30,
|
|
|
|
|
Years Ended September 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
|
2020
|
|
|
2019
|
|
Identifiable assets:
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
Services
|
|
$
|
54,480
|
|
|
$
|
35,695
|
|
|
Services
|
|
$
|
3,127
|
|
|
$
|
2,017
|
|
Products
|
|
|
1,535
|
|
|
|
1,780
|
|
|
Products
|
|
|
23
|
|
|
|
19
|
|
Unallocated corporate
|
|
|
5,578
|
|
|
|
4,505
|
|
|
Unallocated corporate
|
|
|
779
|
|
|
|
681
|
|
|
|
$
|
61,593
|
|
|
$
|
41,980
|
|
|
|
|
$
|
3,929
|
|
|
$
|
2,717
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill, net:
|
|
|
|
|
|
|
|
|
|
Capital expenditures:
|
|
|
|
|
|
|
|
|
Services
|
|
$
|
4,368
|
|
|
$
|
3,617
|
|
|
Services
|
|
$
|
4,781
|
|
|
$
|
5,936
|
|
Products
|
|
|
—
|
|
|
|
—
|
|
|
Products
|
|
|
9
|
|
|
|
29
|
|
Unallocated corporate
|
|
|
—
|
|
|
|
—
|
|
|
Unallocated corporate
|
|
|
1,410
|
|
|
|
913
|
|
|
|
$
|
4,368
|
|
|
$
|
3,617
|
|
|
|
|
$
|
6,200
|
|
|
$
|
6,878
|
|
|
(b)
|
Geographic Information
|
|
|
Years Ended September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Sales to External Customers:
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
56,253
|
|
|
$
|
39,634
|
|
Other North America
|
|
|
148
|
|
|
|
218
|
|
Pacific Rim
|
|
|
2,826
|
|
|
|
2,407
|
|
Europe
|
|
|
1,207
|
|
|
|
1,217
|
|
Other
|
|
|
35
|
|
|
|
140
|
|
|
|
$
|
60,469
|
|
|
$
|
43,616
|
|
|
|
|
|
|
|
|
|
|
Long-lived Assets:
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
28,729
|
|
|
$
|
22,828
|
|
|
|
$
|
28,729
|
|
|
$
|
22,828
|
|
Sales are predominately
to customers located principally in the United States. The Company extends trade credit to its customers on terms that are generally
practiced in the industry. As of and for the years ended September 30, 2020 and 2019, no customers accounted for more than
10 percent of sales or accounts receivable.
13. ACCRUED EXPENSES
As part of a fiscal
2012 restructuring, the Company accrued for lease payments at the cease use date for our United Kingdom facility and have considered
free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements.
Based on these matters, we had a $1,117 reserve for lease related costs and for legal and professional fees and other costs to
remove improvements previously made to the facility. During fiscal 2020, the Company released portions of the reserve for lease
related liabilities that were no longer owed due to the statute of limitations. At September 30, 2020 and September 30,
2019, respectively, we had $168 and $349 reserved for the remaining liability. The reserve is classified as a current liability
on the condensed consolidated balance sheets.
14. RELATED-PARTY TRANSACTIONS
In April 2017,
the Company renewed a consulting agreement with a shareholder, incurring $76 and $75 in fees and reimbursed travel costs in fiscal
2020 and fiscal 2019, respectively. Additionally, the Company has a consulting agreement with LS Associates by which we paid consulting
fees of $64 and $156 in fiscal 2020 and fiscal 2019, respectively. LS Associates is owned in part by our CEO, Robert W. Leasure
Jr. The Company received consulting services form LS Associates prior to Mr. Leasure being elected as CEO and continues to
use services of the consulting firm on an as needed basis.
The Company leases
space from SWL Properties, LLC. SWL Properties is owned by three employees of the company, two of which are officers. The lease
term is seven years, with the possibility of extension for two successive terms of seven years each. The lease also includes an
option to purchase the building during the first five years of the lease at fair market value. The lease is reflected as a financing
lease on the balance sheet. Lease expense incurred was $390 in each of the fiscal years 2020 and 2019.
The Company has an
unsecured promissory note in the initial principal amount of $800 made by PCRS Purchaser, who is an affiliate of the Company. See
description of promissory note in Note 7. In addition, the affiliate leases space to the Company. The initial term of the lease
is five years with the possibility of extension for two successive terms of five years each. The lease is reflected as an operating
lease on the balance sheet. Lease expense incurred was $85 in fiscal 2020.